Hospital contacts due to hepatobiliary adverse events in >5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4): an observational nationwide study applying linkage between DANBIO and national registries

Bente Glintborg, Stylianos Georgiadis, Anne Gitte Loft, Asta Linauskas, Hanne Lindegaard, Oliver Hendricks, Dorte V Jensen, Birgitte Lange Andersen, Kamilla Danebod, Anders Villumsen, Grith Eng, Charlotte Wiell, Natalia Manilo, Salome Kristensen, Johnny Raun, Jolanta Grydehøj, Stavros Chrysidis, Mette Nørgaard, Frank Mehnert, Niels Steen KroghMerete Lund Hetland

Original languageEnglish
JournalAnnals of the Rheumatic Diseases
Issue number6
Pages (from-to)846-848
Number of pages3
Publication statusPublished - 2020


  • Adult
  • Aged
  • Ambulatory Care/statistics & numerical data
  • Anti-Inflammatory Agents, Non-Steroidal/adverse effects
  • Arthritis/drug therapy
  • Biliary Tract Diseases/epidemiology
  • Biosimilar Pharmaceuticals/adverse effects
  • Chemical and Drug Induced Liver Injury/epidemiology
  • Cohort Studies
  • Denmark/epidemiology
  • Etanercept/adverse effects
  • Female
  • Hospitalization/statistics & numerical data
  • Humans
  • Incidence
  • Male
  • Medical Record Linkage
  • Middle Aged
  • Registries

Cite this